Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$1.04
+0.5%
$1.09
$0.98
$4.69
$3.66M1.12239,475 shs107,218 shs
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$1.20
-0.8%
$1.01
$0.81
$8.45
$28.38M0.74128,313 shs68,117 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.22
-6.9%
$3.23
$2.57
$20.48
$19.90M0.639,097 shs25,168 shs
Promis Neurosciences stock logo
PMN
Promis Neurosciences
$0.48
-1.0%
$0.53
$0.47
$2.37
$15.70M-0.0879,574 shs22,203 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
0.00%-1.90%-3.72%-30.07%-59.88%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
0.00%+10.09%+24.56%+23.69%-15.49%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%-2.72%-4.02%-6.40%-46.51%
Promis Neurosciences stock logo
PMN
Promis Neurosciences
0.00%-2.79%-3.96%-30.96%-67.99%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
2.6324 of 5 stars
3.75.00.00.00.00.01.3
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
3.2835 of 5 stars
3.75.00.00.02.70.80.6
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.8519 of 5 stars
0.03.00.00.02.21.70.6
Promis Neurosciences stock logo
PMN
Promis Neurosciences
3.6958 of 5 stars
3.55.00.00.03.80.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
3.33
Buy$14.001,252.66% Upside
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
3.33
Buy$10.00733.33% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Promis Neurosciences stock logo
PMN
Promis Neurosciences
3.00
Buy$4.50837.11% Upside

Current Analyst Ratings Breakdown

Latest CANF, NAII, ENLV, and PMN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2025
Promis Neurosciences stock logo
PMN
Promis Neurosciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$3.00
4/21/2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
4/15/2025
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/3/2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
4/1/2025
Promis Neurosciences stock logo
PMN
Promis Neurosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
$674K5.44N/AN/A$1.76 per share0.59
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/A$1.00 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.17N/AN/A$13.32 per share0.24
Promis Neurosciences stock logo
PMN
Promis Neurosciences
N/AN/AN/AN/A$0.50 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
-$7.63M-$1.79N/AN/AN/AN/AN/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$15.01M-$0.66N/AN/AN/AN/A-57.67%-50.52%8/29/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%N/A
Promis Neurosciences stock logo
PMN
Promis Neurosciences
$2.78M-$0.05N/AN/AN/AN/A-186.19%-98.56%8/6/2025 (Estimated)

Latest CANF, NAII, ENLV, and PMN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/30/2025Q1 2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$0.16-$0.15+$0.01-$0.15N/AN/A
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/12/2025Q1 2025
Promis Neurosciences stock logo
PMN
Promis Neurosciences
-$0.14-$0.21-$0.07-$0.21N/AN/A
3/31/2025Q4 2024
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$0.16-$0.23-$0.07-$0.23N/AN/A
3/31/2025Q4 2024
Promis Neurosciences stock logo
PMN
Promis Neurosciences
-$0.14-$0.02+$0.12-$0.02N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
N/AN/AN/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Promis Neurosciences stock logo
PMN
Promis Neurosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
N/A
2.93
N/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/A
7.20
7.20
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
Promis Neurosciences stock logo
PMN
Promis Neurosciences
N/A
3.36
3.36
CompanyEmployeesShares OutstandingFree FloatOptionable
Can-Fite BioPharma Ltd. stock logo
CANF
Can-Fite BioPharma
83.54 millionN/ANot Optionable
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
7023.65 million20.75 millionOptionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
Promis Neurosciences stock logo
PMN
Promis Neurosciences
532.69 million30.69 millionNot Optionable

Recent News About These Companies

ProMIS Neurosciences reports FY24 EPS 11c vs. ($1.07) last year
ProMIS Neurosciences doses first patiets in Phase 1b PRECISE-AD trial
ProMIS Neurosciences seperates from COO Malenfant, terminates COO position
ProMIS Neurosciences anticipates PRECISE-AD interim patient data in 1H26

New MarketBeat Followers Over Time

Media Sentiment Over Time

Can-Fite BioPharma stock logo

Can-Fite BioPharma NYSE:CANF

$1.03 +0.01 (+0.49%)
Closing price 06/27/2025 03:53 PM Eastern
Extended Trading
$1.95 +0.92 (+88.41%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Enlivex Therapeutics stock logo

Enlivex Therapeutics NASDAQ:ENLV

$1.20 -0.01 (-0.83%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$8.45 +7.25 (+604.17%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.22 -0.24 (-6.94%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$20.48 +17.26 (+536.02%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Promis Neurosciences stock logo

Promis Neurosciences NASDAQ:PMN

$0.48 0.00 (-0.97%)
Closing price 06/27/2025 03:47 PM Eastern
Extended Trading
$0.58 +0.10 (+20.78%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.